Difficult-to-treat women for controlled ovarian hyperstimulation: tips and tricks

References

• Hanoch J, Lavy Y, Holzer H et al. Young low responders protected from untoward effects of reduced ovarian response. Fertil. Steril.69, 1001–1004 (1998).
   PubMed Web of Science ®Google Scholar
• Feldman B, Seidman DS, Levron J et al. In vitro fertilization following natural cycles in poor responders. Gynecol. Endocrinol.15, 328–334 (2001).
   PubMed Web of Science ®Google Scholar
• Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J. Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum. Reprod. Update9, 61–76 (2003).
   PubMed Web of Science ®Google Scholar
• Pellicer A, Lightman A, Diamond MP, Russell JB, DeCherney AH. Outcome of in vitro fertilization in women with low response to ovarian stimulation. Fertil. Steril.47, 812–815 (1987).
   PubMed Web of Science ®Google Scholar
• Jenkins JM, Davies DW, Devonport H et al. Comparison of ‘poor’ responders with ‘good’ responders using a standard buserelin/human menopausal gonadotrophin regime for in vitro fertilization. Hum. Reprod.6, 918–921 (1991).
   PubMed Web of Science ®Google Scholar
• Bassil S, Godin PA, Donnez J. Outcome of in vitro fertilization through natural cycles in poor responders. Hum. Reprod.14(5), 1262–1265 (1999).
   PubMed Web of Science ®Google Scholar
• Papaleo E, De Santis L, Fusi F et al. Natural cycle as first approach in aged patients with elevated follicle-stimulating hormone undergoing intracytoplasmic sperm injection: a pilot study. Gynecol. Endocrinol.22(7), 351–354 (2006).
   PubMed Web of Science ®Google Scholar
• Schimberni M, Morgia F, Colabianchi J et al. Natural-cycle in vitro fertilization in poor responder patients: a survey of 500 consecutive cycles. Fertil. Steril.92(4), 1297–1301 (2009).
   PubMed Web of Science ®Google Scholar
• Janssens RM, Lambalk CB, Vermeiden JP, Schats R, Schoemaker J. In vitro fertilization in a spontaneous cycle: easy, cheap and realistic. Hum. Reprod.15, 314–418 (2000).
   PubMed Web of Science ®Google Scholar
• Tan SL, Royston P, Campbell et al. Cumulative conception and livebirth rates after in vitro fertilization. Lancet339, 1390–1394 (1992).
   PubMed Web of Science ®Google Scholar
• Nargund G, Waterstone J, Bland JM, Philips Z, Parsons J, Campbell S. Cumulative conception and live birth rates in natural (unstimulated) IVF cycles. Hum. Reprod.16(2), 259–262 (2002).
   Google Scholar
• Munnè S, Magli C, Adler A et al. Treatment related chromosome abnormalities in human embryos. Hum. Reprod.12, 780–784 (1997).
   PubMed Web of Science ®Google Scholar
• Lass A, Peat D, Avery S, Brinsden P. Histological evaluation of endometrium on the day of oocyte retrieval after gonadotrophin-releasing hormone agonist-follicle stimulating hormone ovulation induction for in vitro fertilization. Hum. Reprod.13, 3203–3205 (1998).
   PubMedGoogle Scholar
• Rongières-Bertrand C, Olivennes F, Righini C et al. Revival of the natural cycles in in vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Hum. Reprod.14(3), 683–688 (1999).
   PubMed Web of Science ®Google Scholar
• Elizur SE, Aslan D, Shulman A, Weisz B, Bider D, Dor J. Modified natural cycle using GnRH antagonist can be an optional treatment in poor responders undergoing IVF. J. Assist. Reprod. Genet.22(2), 75–79 (2005).
   PubMed Web of Science ®Google Scholar
• Castelo Branco A, Achour-Frydman N, Kadoch J, Fanchin R, Tachdjian G, Frydman R. In vitro fertilization and embryo transfer in seminatural cycles for patients with ovarian aging. Fertil. Steril.84(4), 875–880 (2005).
   PubMedGoogle Scholar
• Ubaldi FM, Rienzi L, Ferrero S et al. Management of poor responders in IVF. Reprod. Biomed. Online10(2), 235–246 (2005).
   PubMed Web of Science ®Google Scholar
• Kolibianakis E, Zikopoulos K, Camus M, Tournaye H, Van Steirteghem A, Devroey P. Modified natural cycle for IVF does not offer a realistic chance of parenthood in poor responders with high day 3 FSH levels, as a last resort prior to oocyte donation. Hum. Reprod.19, 2545–2549 (2004).
   PubMedGoogle Scholar
• Garcia-Velasco JA, Isaza V, Requena A, Martinez-Salazar FJ, Landazabal A, Remohi J. High doses of gonadotropins combined with stop versus non-stop protocol of GnRH analogue administration in low responser IVF patients: a prospective, randomized, controlled trial. Hum. Reprod.15, 2292–2296 (2000).
   PubMed Web of Science ®Google Scholar
• Dirnfeld M, Fruchter O, Yshai D, Lissak A, Ahdut A, Abramovici H. Cessation of gonadotropin-releasing hormone analogue (GnRH-a) upon down-regulation versus conventional long GnRH-a protocol in poor responsers undergoing in vitro fertilization. Fertil. Steril.72, 406–411 (1999).
   PubMed Web of Science ®Google Scholar
• Weissman A, Farhi J, Royburt M et al. Prospective evaluation of 2 stimulation protocols for low responders who were undergoing in vitro fertilization-embryo transfer. Fertil. Steril.79, 886–892 (2003).
   PubMed Web of Science ®Google Scholar
• Vollenhoven B, Osianlis T, Catt J. Is there an ideal stimulation regimen for IVF for poor responders and does it change with age? J. Assist. Reprod. Genet.25, 523–529 (2008).
   PubMed Web of Science ®Google Scholar
• Akman MA, Erden HF, Tosun SB, Bayazitet N, Aksoy E, Bahceci M. Comparison of agonistic flare-up protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum. Reprod.16, 868–870 (2001).
   PubMed Web of Science ®Google Scholar
• Cheung LP, Lam PM, Lok IH et al. GnRH antagonist versus long GnRH agonist protocols in poor responders undergoing IVF: a randomized controlled trial. Hum. Reprod.20, 616–621 (2005).
   PubMed Web of Science ®Google Scholar
• Franco JG Jr, Baruffi RL, Mauri AL et al. GnRH agonist versus GnRH antagonist in poor responders: a meta analysis. Reprod. Biomed. Online13, 618–627 (2006).
   PubMed Web of Science ®Google Scholar
• Mahutte NG, Arici A. Role of gonadotropin-releasing hormone antagonists in poor responders. Fertil. Steril.87, 241–249 (2007).
   PubMed Web of Science ®Google Scholar
• Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta analysis. Reprod. Biomed. Online13, 628–638 (2006).
   PubMed Web of Science ®Google Scholar
• Berin I, Stein DE, Keltz MD. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization. Fertil. Steril.93(2), 360–363 (2010).
   PubMedGoogle Scholar
• Marci R, Caserta D, Dolo V, Tatone C, Pavan A, Moscarini M. GnRH antagonist in IVF poor responder patients: results of a randomized trial. Reprod. Biomed. Online11, 189–193 (2005).
   PubMed Web of Science ®Google Scholar
• Lainas TG, Sfontouris IA, Papanikolaou EG et al. Flexible GnRH antagonist versus flare-up GnRH agoinst protocol in poor responders treated by IVF: a randomized controlled trial. Hum. Reprod.23, 1355–1358 (2008).
   PubMed Web of Science ®Google Scholar
• Frankfurter A, Dayal M, Dubey A, Peak D, Gindoff P. Novel folliclar-phase gonadotropin-releasing hormone antagonist simulation protocol for in vitro fertilization in the poor responder. Fertil. Steril.88, 1442–1445 (2007).
   PubMed Web of Science ®Google Scholar
• Nilsson L, Andersen AN, Lindenberg S, Hausken J, Andersen CY, Kahn JA. Ganirelix for luteolysis in poor responder patients undergoing IVF treatment: a Scandinavian multicenter ‚extended pilot study‘. Acta Obstet. Gynecol. Scand.89(6), 828–831 (2010).
   PubMed Web of Science ®Google Scholar
• Pandian Z, McTavish AR, Aucott L, Hamilton MP, Bhattacharya S. Interventions for ‘poor responders’ to controlled ovarian hyperstimulation (COH) in in vitro fertilisation (IVF). Cochrane Database Syst. Rev.20(1), CD00437 (2010).
   Google Scholar
• Siristatidis CS, Hamilton MP. What should be the maximum FSH dose in IVF/ICSI in poor responders? J. Obstet. Gynaecol.27(4), 401–405 (2007).
   PubMedGoogle Scholar
• Rombauts L. Is there a recommended maximum starting dose of FSH in IVF? J. Assist. Reprod. Genet.24(8), 343–349 (2007).
   PubMed Web of Science ®Google Scholar
• Wei Z, Cheng X, Li H et al. Effects of prolonging administration gonadotropin on unexpectedly poor ovarian responders undergoing in vitro fertilization. Reprod. Biol. Endocrinol.8, 26 (2010).
   PubMedGoogle Scholar
• Andreeva P. HP-FSH (Fostimon) – a matter of choice in women with low ovarian response. Akush Ginekol.47(3), 56–61 (2008).
   PubMedGoogle Scholar
• Goverde AJ, McDonnel J, Schat R, Vermeiden JPW, Homburg R, Lambalk CB. Ovarian response to standard gonadotropin stimulation for IVF in couples with idiopathic and male subferility. Hum. Reprod.20, 1573–1577 (2005).
   PubMedGoogle Scholar
• Caglar GS, Asimakopoulos B, Nikolettos K, AI-Hasani S. Recombinant LH in ovarian stimulation. Reprod. Biomed. Online10, 774–785 (2005).
   PubMed Web of Science ®Google Scholar
• Arrenetxea G, Agirregoikoa JA, Jimenez MR, Loprz de Larruzea A, Ganzabal T, Carbonero K. Ovarian response and pregnancy outcome in poor-responser women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertil. Steril.89, 546–553 (2008).
   PubMedGoogle Scholar
• Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum. Reprod.15(10), 2129–2132 (2000).
   PubMed Web of Science ®Google Scholar
• Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum. Reprod.21(11), 2845–2849 (2006).
   PubMed Web of Science ®Google Scholar
• Barad DH, Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. Fertil. Steril.84(3), 756 (2005).
   PubMed Web of Science ®Google Scholar
• Sönmezer M, Ozmen B, Cil AP et al. Dehydroepiandrosterone supplementation improves ovarian response and cycle outcome in poor responders. Reprod. Biomed. Online19(4), 508–513 (2009).
   PubMed Web of Science ®Google Scholar
• Mamas L, Mamas E. Dehydroepiandrosterone supplementation in assisted reproduction: rationale and results. Curr. Opin. Obstet. Gynecol.21(4), 306–308 (2009).
   PubMed Web of Science ®Google Scholar
• Hillier SG, Whitelaw PF, Smyth CD. Follicular oestrogen synthesis: the ‘two-cell, two-gonadotrophin’ model revisited. Mol. Cell Endocrinol.100(1–2), 51–54 (1994).
   PubMed Web of Science ®Google Scholar
• Vendola K, Zhou J, Wang J, Famuyiwa OA, Bievre M, Bondy CA. Androgens promote oocyte insulin-like growth factor I expression and initiation of follicle development in the primate ovary. Biol. Reprod.61(2), 353–357 (1999).
   PubMed Web of Science ®Google Scholar
• Frattarelli JL, Peterson EH. Effect of androgen levels on in vitro fertilization cycles. Fertil. Steril.81(6), 1713–1714 (2004).
   PubMed Web of Science ®Google Scholar
• Barbieri RL, Sluss PM, Powers RD et al. Association of body mass index, age, and cigarette smoking with serum testosterone levels in cycling women undergoing in vitro fertilization. Fertil. Steril.83(2), 302–382 (2005).
   PubMed Web of Science ®Google Scholar
• Homburg R, Eshel A, Abdulla HI, Jacobs HS. Growth hormone facilitates ovulation induction by gonadotrophins. Clin. Endocrinol.29, 113–118 (1988).
   PubMed Web of Science ®Google Scholar
• Barecca A, Artini PG, Del Monte P, Ponzani P, Pasquini P, Cariola G. In vivo and in vitro effect of growth hormone on estradiol secretion by granulosa cells. J. Clin. Endocrinol. Metab.77, 61–67 (1993).
   PubMed Web of Science ®Google Scholar
• Dor J, Seidman DS, Amudai E, Bider D, Levran D, Mashiach S. Adjuvant growth hormone therapy in poor responders to in vitro fertilization: a prospective randomized placebo-controlled double-blind study. Hum. Reprod.10, 40–43 (1995).
   PubMed Web of Science ®Google Scholar
• Harper K, Proctor M, Hughes E. Growth hormone for in vitro fertilization. Cochrane Database Syst. Rev.3, CD000099 (2003).
   Google Scholar
• Tesarik J, Hazout A, Mendoza C. Improvement of delivery and live birth rates after ICSI in women aged >40 years by ovarian co-stimulation with growth hormone. Hum. Reprod.20, 2536–2541 (2005).
   PubMed Web of Science ®Google Scholar
• Kucuk T, Kozinoglu H, Kaba A. Growth hormone co-treatment within a GnRH agonist long protocol in patients with poor ovarian response: a prospective, randomized, clinical trial. J. Assist. Reprod. Genet.25(4), 123–127 (2008).
   PubMed Web of Science ®Google Scholar
• Kolibianakis EM, Venetis CA, Diedrich K, Tarlatzis BC, Griesinger G. Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in vitro fertilization: a systematic review and meta-analysis. Hum. Reprod. Update15(6), 613–622 (2009).
   PubMed Web of Science ®Google Scholar
• Duffy JM, Ahmad G, Mohiyiddeen L, Nardo LG, Watson A. Growth hormone for in vitro fertilization. Cochrane Database Syst. Rev.20(1), CD000099 (2010).
   Google Scholar
• Frattarelli JL, Hill MJ, McWilliams GDE, Miller KA, Bergh PA, Scott RT. A luteal estradiol protocol for expected poor responders improves embryo number and quality. Fertil. Steril.89, 1118–1122 (2008).
   PubMed Web of Science ®Google Scholar
• Hill MJ, McWilliams GDE, Miller KA, Scott RT, Frattarelli JL. A luteal estradiol protocol for anticipated poor-responders improves delivery rates. Fertil. Steril.91(3), 739–743 (2009).
   PubMed Web of Science ®Google Scholar
• Fisch JD, Keskintepe L, Sher G. Gonadotropin-releasesing hormone agonist/antagonist conversion with estrogen priming in low responders with prior in vitro fertilization failure. Fertil. Steril.89, 342–347 (2008).
   PubMedGoogle Scholar
• Weil S, Vendola K, Zhou J, Bondy CA. Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development. J. Clin. Endocrinol. Metab.84(8), 2951–2956 (1999).
   PubMed Web of Science ®Google Scholar
• Fábregues F, Peñarrubia J, Creus M et al. Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial. Hum. Reprod.24(2), 349–359 (2009).
   PubMed Web of Science ®Google Scholar
• Balasch J, Fábregues F, Peñarrubia J et al. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in low- responder IVF patients with normal basal concentration of FSH. Hum. Reprod.21, 1884–1893 (2006).
   PubMed Web of Science ®Google Scholar
• Polyzos NP, Tzioras S, Badawy AM, Valachis A, Dritsas C, Mauri D. Aromatase inhibitors for female infertility: a systematic review of the literature. Reprod. Biomed. Online19(4), 456–471 (2009).
   PubMed Web of Science ®Google Scholar
• Feigenberg T, Simon A, Ben-Meir A, Gielchinsky Y, Laufer N. Role of androgens in the treatment of patients with low ovarian response. Reprod. Biomed. Online19(6), 888–898 (2009).
   PubMedGoogle Scholar
• Stein IF, Levanthal ML. Amenorrhea associated with bilateral polycystic ovaries. Stein Am. J. Obstet. Gynecol.29, 181–191 (1935).
   Google Scholar
• Artini PG, Di Berardino OM, Simi G et al. Best methods for identification and treatment of PCOS. Minerva Ginecol.62(1), 33–48 (2010).
   PubMedGoogle Scholar
• ESHRE/ASRM. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil. Steril.81, 19–25 (2004).
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod.19, 41–47 (2004).
   PubMed Web of Science ®Google Scholar
• Azziz EC. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J. Clin. Endocrinol. Metab.91(11), 4237–4245 (2009).
   Google Scholar
• MacDougall MJ, Tan SL, Jacobs HS. In vitro fertilization and the ovarian hyperstimulation syndr ome. Hum. Reprod.7, 597–600 (1992).
   PubMedGoogle Scholar
• Olivennes F, Belaisch-Allart J, Emperaire JC et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil. Steril.73(2), 314–320 (2000).
   PubMed Web of Science ®Google Scholar
• Lin YH, Seow KM, Hsieh BC et al. Application of GnRH antagonist in combination with clomiphene citrate and hMG for patients with exaggerated ovarian response in previous IVF/ICSI cycles. J. Assist. Reprod. Genet.24(8), 331–336 (2007).
   PubMedGoogle Scholar
• Sovino H, Sir-Petermann T, Devoto L. Clomiphene citrate and ovulation induction. Reprod. Biomed. Online4(3), 303–310 (2002).
   PubMedGoogle Scholar
• Nugent D, Vandekerckhove P, Hughes E, Arnot M, Lilford R. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst. Rev.4, CD000410 (2000).
   Google Scholar
• Bayram N, van Wely M, van Der Veen F. Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst. Rev.2, CD002121 (2001).
   Google Scholar
• Hughes E, Collins J, Vandekerckhove P. Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. Cochrane Database Syst. Rev.2, CD000087 (2000).
   PubMedGoogle Scholar
• Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PM, van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum. Reprod.23(2), 310–315 (2008).
   PubMed Web of Science ®Google Scholar
• Aboulghar M, Saber W, Amin Y, Aboulghar M, Mansour R, Serour G. Prospective, randomized study comparing highly purified urinary follicle-stimulating hormone (FSH) and recombinant FSH for in vitro fertilization/intracytoplasmic sperm injection in patients with polycystic ovary syndrome Fertil. Steril.94(6), 2332–2334 (2010).
   PubMedGoogle Scholar
• Hamburg R, Berkovitz D, Frachi J, Feldbery D, Ashkenazi J, Ben-Rafael Z. Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome. Fertil. Steril.59, 527–531 (1993).
   PubMedGoogle Scholar
• Homburg R, Berkowitz D, Hervy T, Feldberg D, Ashkenazi J, Ben-Rafael Z. In vitro fertilization and embryo transfer for the treatment of infertility associated with polycystic ovary syndrome. Fertil. Steril.60, 858–863 (1993).
   PubMed Web of Science ®Google Scholar
• Hughes E, Collins J, Vandekerckhove P. Gonadotrophin-releasing hormone analogue as an adjunct to gonadotropin therapy for clomiphene-resistant polycystic ovarian syndrome. Cochrane Database Syst. Rev.2, CD000097 (2000).
   Google Scholar
• Kolibianakis EM, Collins J, Tarlatzis BC, Devroy P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum. Reprod. Update12(6), 651–671 (2006).
   PubMed Web of Science ®Google Scholar
• Al-Inany HG, Abou-setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod. Biomed. Online14(5), 640–649 (2007).
   PubMed Web of Science ®Google Scholar
• Kdous M, Chaker A, Bouyahia M, Zhioua F, Zhioua A. Increased risk of early pregnancy loss and lower live birth rate with GnRH antagonist vs. long GnRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation. Tunis. Med.87(12), 834–842 (2009).
   PubMedGoogle Scholar
• Lainas TG, Sfontouris IA, Zorzovilis IZ et al. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Hum. Reprod.25(3), 683–689 (2010).
   PubMed Web of Science ®Google Scholar
• Tehraninejad ES, Nasiri R, Rashidi B, Haghollahi F, Ataie M. Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients. Arch. Gynecol. Obstet.282(3), 319–325 (2010).
   PubMed Web of Science ®Google Scholar
• Hamilton-Fairly D, Kiddy D, Watson H, Sagle M, Franks S. Low dose gonadotrophin therapy for induction of ovulation in 100 women with PCOS. Hum. Reprod.6, 1095–1099 (1991).
   PubMedGoogle Scholar
• Homburg R, Levy T, Ben-Rafael Z. A comparative prospective study of conventional regimen withchronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome. Fertil. Steril.63(4), 729–733 (1995).
   PubMed Web of Science ®Google Scholar
• Christin-Maitre S, Hugues JN; on behalf of the Recombinant FSH Study Group. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum. Reprod.18, 1626–1631 (2003).
   PubMed Web of Science ®Google Scholar
• Orvieto R, Homburg R. Chronic ultra-low dose follicle-stimulating hormone regimen for patients with polycystic ovary syndrome: one click, one follicle, one pregnancy. Fertil. Steril.91(4 Suppl. 1), 1533–1535 (2009).
   PubMed Web of Science ®Google Scholar
• Rabinovici J, Kushnir O, Shalev J, Goldenberg M, Blankstein J. Rescue of menotrophin cycles prone to develop ovarian hyperstimulation. Br. J. Obstet. Gynaecol.94, 1098–1102 (1987).
   PubMedGoogle Scholar
• Sher G, Salem R, Feinman M, Dodge S, Zouves C, Knutzen V. Eliminating the risk of life-endangering complications following ovarian overstimulation with menotropin fertility agents: a report on women undergoing in vitro fertilization and embryo transfer. Obstet. Gynecol.81, 1009–1011 (1993).
   PubMed Web of Science ®Google Scholar
• Fluker MR, Hooper WM, Yuzpe AA. Withholding gonadotropins (‘coasting’) to minimize the risk of ovarian hyperstimulation during superovulation and in vitro fertilization-embryo transfer cycles. Fertil. Steril.71, 294–301 (1999).
   PubMed Web of Science ®Google Scholar
• Delvigne A, Rozenberg S. A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients. Hum. Reprod. Update8, 291–296 (2002).
   PubMed Web of Science ®Google Scholar
• D’Angelo A, Amso N. ‘Coasting’ (with holding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst. Rev.3, CD002811 (2002).
   Google Scholar
• Delvigne A, Rozenberg S. Preventive attitude of physicians to avoid OHSS in IVF patients. Hum. Reprod.16, 2491–2495 (2001).
   PubMed Web of Science ®Google Scholar
• Kolibianakis EM, Papanikolaou EG, Tournaye H, Camus M, Van Steirteghem AC, Devroey P. Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone. Fertil. Steril.88, 1382–1388 (2007).
   PubMedGoogle Scholar
• Aboulghar M. Symposium. Update on prediction and management of OHSS. Prevention of OHSS. Reprod. Biomed. Online19(1), 33–42 (2009).
   PubMedGoogle Scholar
• Chen D, Burmeister L, Goldschlag D, Rosenwaks Z. Ovarian hyperstimulation syndrome: strategies for prevention. Reprod. Biomed. Online7, 43–49 (2003).
   PubMedGoogle Scholar
• Schmidt DW, Maier DB, Nulsen JC, Benadiva CA. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization. Fertil. Steril.82, 841–846 (2004).
   PubMedGoogle Scholar
• Abdalla HI, Ah-Moye M, Brinsden P, Howe DL, Okonofua F, Craft I. The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization program. Fertil. Steril.48, 958–963 (1987).
   PubMed Web of Science ®Google Scholar
• Humaidan P, Ejdrup Bredkjær H, Bungum L et al. GnRH agonist (Buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomised study. Hum. Reprod.20, 1213–1220 (2005).
   PubMed Web of Science ®Google Scholar
• Kolibianakis EM, Schultze-Mosgau A, Schroer A et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of hCG in patients undergoing IVF with GnRH antagonists. Hum. Reprod.20, 2887–2892 (2005).
   PubMed Web of Science ®Google Scholar
• Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil. Steril.56, 213–220 (1991).
   PubMed Web of Science ®Google Scholar
• Damewood MD, Shen W, Zacur HA, Schlaff WD, Rock JA, Wallach EE. Disappearance of exogenously administered human chorionic gonadotropin. Fertil. Steril.52, 945–953 (1989).
   Google Scholar
• Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil. Steril.94(2), 389–400 (2010).
   PubMed Web of Science ®Google Scholar
• Melo M, Busso CE, Bellver J et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reprod. Biomed. Online19(4), 486–492 (2009).
   PubMed Web of Science ®Google Scholar
• Manzanares MA, Gómez-Palomares JL, Ricciarelli E, Hernández ER. Triggering ovulation with gonadotropin-releasing hormone agonist in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels. Fertil. Steril.93(4), 1215–1219 (2010).
   PubMed Web of Science ®Google Scholar
• Humaidan P. GnRHa triggering of final oocyte maturation followed by one bolus of 1500 IU hCG rescues the luteal phase and seems to prevent the risk of early onset OHSS in high-risk patients: a prospective proof-of-concept study. Reprod. Biomed. Online18, 630–634 (2009).
   PubMed Web of Science ®Google Scholar
• Humaidan P, Papanikolaou EG, Tarlatzis BC. GnRHa to trigger final oocyte maturation: a time to reconsider . Hum. Reprod.24(10), 2389–2394 (2009).
   PubMed Web of Science ®Google Scholar
• Vandermolen DT, Ratts VS, Evans WS, Stowall DW, Kauma SW, Nestler JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil. Steril.75, 310–315 (2001).
   PubMed Web of Science ®Google Scholar
• Yarali H, Yildiz BO, Demirol A et al. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome. Hum. Reprod.17, 289–294 (2002).
   PubMed Web of Science ®Google Scholar
• Costello MF, Chapman M, Conway U. A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome. Hum. Reprod.21(6), 1387–1399 (2006).
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Orio F Jr et al. A randomized controlled trial evaluating metformin pre-treatment and co-administration in non obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination. Hum. Reprod.29, 2879–2886 (2005).
   Google Scholar
• Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Freitas V. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst. Rev.15(2), CD006105 (2009).
   Google Scholar
• Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil. Steril.91(5), 1750–1754 (2009).
   PubMed Web of Science ®Google Scholar
• Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol. Endocrinol.26(4), 275–280 (2010).
   PubMed Web of Science ®Google Scholar
• Altintas D, Kokcu A, Tosun M, Cetinkaya MB, Kandemir B. Comparison of the effects of cetrorelix, a GnRH antagonist, and leuprolide, a GnRH agonist, on experimental endometriosis J. Obstet. Gynaecol.34(6), 1014–1019 (2008).
   Google Scholar
• Catenacci M, Falcone T. The effect of endometriosis on in vitro fertilization outcome. Minerva Ginecol.60(3), 209–221 (2008).
   PubMedGoogle Scholar
• Garcia-Velasco JA, Somigliana E. Management of endometriomas in women requiring IVF: to touch or not to touch. Hum. Reprod.24(3), 496–501 (2009).
   PubMed Web of Science ®Google Scholar
• Kennedy S, Bergqvist A, Chapron C et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum. Reprod.20, 2698–2704 (2005).
   PubMed Web of Science ®Google Scholar
• Practice Committee of the American Society for Reproductive Medicine. Endometriosis and infertility. Fertil. Steril.86(5 Suppl. 1), 156–160 (2006).
   PubMed Web of Science ®Google Scholar
• Vercellini P, Somigliana E, Vigano P, Abbiati A, Barbara G, Crosignanil PG. Endometriosis: current therapies and new pharmacological developments. Drugs69, 649–675 (2009).
   PubMed Web of Science ®Google Scholar
• Sallam HN, Garcia-Velasco JA, Dias S, Arici A. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis, Cochrane Database Syst. Rev.1, CD004635 (2006).
   Google Scholar
• Shahine LK, Burney RO, Behr B et al. Embryo quality before and after surgical treatment of endometriosis in infertile patients. J. Assist. Reprod. Genet.26, 69–67 (2009).
   PubMed Web of Science ®Google Scholar
• de Ziegler D, Borghese B, Chapron C. Endometriosis and infertility: pathophysiology and management. Lancet376(9742), 730–738 (2010).
   PubMed Web of Science ®Google Scholar
• Pabuccu R, Onalan G, Kaya C. GnRH agonist and antagonist protocols for stage I–II endometriosis and endometrioma in in vitro fertilization/intracytoplasmic sperm injection cycles. Fertil. Steril.88(4), 832–839 (2007).
   PubMed Web of Science ®Google Scholar
• Mijatovic V, Florijn E, Halim N, Schats R, Hompes P. Adenomyosis has no adverse effects on IVF/ICSI outcomes in women with endometriosis treated with long-term pituitary down-regulation before IVF ICSI. Eur. J. Obstet. Gynecol. Reprod. Biol.151(1), 62–65 (2010).
   PubMed Web of Science ®Google Scholar
• Gong F, Tang Y, Zhang H, Lu G. Modified super-long down-regulation protocol improved the outcome of in vitro fertilization-embryo transfer in infertile patients. Zhong Nan Da Xue Xue Bao Yi Xue Ban34(3), 185–189 (2009).
   PubMedGoogle Scholar
• Benschop L, Farquhar C, van der Poel N, Heineman MJ. Interventions for women with endometrioma prior to assisted reproductive technology. Cochrane Database Syst. Rev.11, CD008571 (2010).
   PubMed Web of Science ®Google Scholar